Analysts have been eager to weigh in on the Healthcare sector with new ratings on Audentes Therapeutics (BOLD) and Regulus (RGLS).
Audentes Therapeutics (BOLD)
H.C. Wainwright analyst Debjit Chattopadhyay maintained a Buy rating on Audentes Therapeutics today and set a price target of $48. The company’s shares closed yesterday at $37.05.
Chattopadhyay said:
“Our $48 target on shares of Audentes is linked to a 12- year DCF-based, sum-of-the-parts analysis, which includes commercial implications for: (1) AT132 being developed for XLMTM; (2) AT702 being developed for DMD exon mutations 1-5; and (3) AT845 that is being advanced as a one-and-done approach for Pompe disease.”
According to TipRanks.com, Chattopadhyay is a 2-star analyst with an average return of 0.4% and a 43.8% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Voyager Therapeutics Inc, and Mersana Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Audentes Therapeutics with a $43.14 average price target, representing a 16.4% upside. In a report issued on May 2, Cowen & Co. also maintained a Buy rating on the stock.
See today’s analyst top recommended stocks >>
Regulus (RGLS)
Wedbush analyst Liana Moussatos reiterated a Hold rating on Regulus today and set a price target of $1. The company’s shares closed yesterday at $1.20, close to its 52-week low of $0.80.
According to TipRanks.com, Moussatos is ranked 0 out of 5 stars with an average return of -7.8% and a 35.1% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Allena Pharmaceuticals Inc, and Aquestive Therapeutics Inc.
Currently, the analyst consensus on Regulus is a Hold with an average price target of $2.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
